Ernexa Therapeutics Inc. (ERNA)

Market Cap	11.85M
Revenue (ttm)	1,000
Net Income (ttm)	-18.36M
Shares Out	7.85M
EPS (ttm)	-3.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,245
Open	1.490
Previous Close	1.520
Day's Range	1.480 - 1.521
52-Week Range	1.090 - 14.400
Beta	6.69
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2025

About ERNA

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: ERNA
• Website: https://www.ernexatx.com

Financial Performance

In 2024, Ernexa Therapeutics's revenue was $582,000, an increase of 755.88% compared to the previous year's $68,000. Losses were -$44.56 million, 105.5% more than in 2023.